(Q40930334)

24 September 2017

Metformin use improves the survival of diabetic combined small-cell lung cancer patients (English)

1 reference

24 September 2017

1 reference

Fanming Kong

1

1 reference

24 September 2017

Fangfang Gao

2

1 reference

24 September 2017

Honggen Liu

3

1 reference

24 September 2017

Liwei Chen

4

1 reference

24 September 2017

Rongxiu Zheng

5

1 reference

24 September 2017

Jianchun Yu

6

1 reference

24 September 2017

Xiaojiang Li

7

1 reference

24 September 2017

Geli Liu

8

1 reference

24 September 2017

Yingjie Jia

9

1 reference

24 September 2017

language of work or name

1 reference

16 May 2015

1 reference

24 September 2017

1 reference

24 September 2017

36

1 reference

24 September 2017

10

1 reference

24 September 2017

8101-8106

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-015-3549-1

24 September 2017

0 references

cites work

Mixed small cell and non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Type 2 diabetes mellitus and risk of oral cancer and precancerous lesions: a meta-analysis of observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Metabolic syndrome and breast cancer: is there a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Survival of patients with stage IV lung cancer with diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Combined SCLC clinical and pathologic characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Combined small-cell and non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

The effect of metformin and thiazolidinedione use on lung cancer in diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Immune-mediated antitumor effect by type 2 diabetes drug, metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Molecular mechanism of action of metformin: old or new insights?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Metformin prevents tobacco carcinogen--induced lung tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3549-1

Attenuating tumour angiogenesis: a preventive role of metformin against breast cancer

21 January 2018

1 reference

12 December 2020

Population-based cohort studies of type 2 diabetes and stomach cancer risk in Chinese men and women

1 reference

12 December 2020

Probability of pancreatic cancer following diabetes: a population-based study

1 reference

12 December 2020

Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People's Republic of China

1 reference

12 December 2020

Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes

1 reference

12 December 2020

Small-cell lung cancer

1 reference

12 December 2020

Pattern of increasing HbA1c levels in patients with diabetes mellitus before clinical detection of pancreatic cancer - a population-based nationwide case-control study

1 reference

12 December 2020

Do variants associated with susceptibility to pancreatic cancer and type 2 diabetes reciprocally affect risk?

1 reference

12 December 2020

Obesity and diabetes epidemics: cancer repercussions

1 reference

12 December 2020

Association between diabetes mellitus and adverse characteristics of breast cancer at presentation

1 reference

12 December 2020

Diabetes mellitus and risk of thyroid cancer: a meta-analysis

1 reference

12 December 2020

10.1007/S13277-015-3549-1

Identifiers

DOI

1 reference

Dimensions Publication ID

24 September 2017

0 references

1 reference